Business Context and Reporting Period
This Form 8-K, dated January 11, 2012, reports on Illumina, Inc.'s preliminary financial results for the fiscal quarter ended January 1, 2012. The data was presented by CEO Jay Flatley at the J.P. Morgan Healthcare Conference on January 10, 2012. The figures are unaudited.
Key Financial Metrics
- Revenue: Approximately $250 million for the quarter, representing annual revenue just over $1 billion.
- Earnings Per Share (EPS): Estimated pro forma EPS of $0.34.
- Book-to-Bill Ratio: 1.2 for the fourth quarter.
- Order Growth: Sequencing consumable and Infinium orders grew 60% sequentially; record overall microarray orders.
- Shipment Growth: Sequential growth in instruments, sequencing consumables, and services.
- Geographic Performance: APAC and Europe shipments grew over 20% sequentially; US shipments were stable.
Material Changes Versus Prior Period
- Sequential Revenue Growth: 6% increase over the third quarter.
- Year-Over-Year Revenue Growth: 17% increase.
- Year-Over-Year Earnings Growth: 17% increase in pro forma EPS.
- Operational Efficiency: Management cited successful cost controls implemented after the third quarter as a driver for earnings performance.
Guidance, Outlook, and Risks
The filing provides preliminary results rather than formal forward-looking guidance. Management expressed satisfaction with the incoming order rate and the recovery in APAC and Europe markets. The report notes that the information is unaudited and is furnished rather than filed for purposes of Section 18 of the Exchange Act, meaning it cannot be incorporated by reference into other SEC filings. No specific risks or contingencies were detailed in this excerpt beyond the standard unaudited nature of the data.
Investor Verification Checklist
- Verify the final audited Q4 2011 financial statements when the 10-K is filed to confirm the $250 million revenue and $0.34 EPS estimates.
- Review the full transcript (Exhibit 99.1) for detailed breakdowns of instrument versus consumable revenue.
- Monitor subsequent filings for confirmation of the 60% sequential growth in sequencing consumable orders.
- Confirm the impact of cost controls on operating margins in the official quarterly report.